Valuation : Fortress Biotech, Inc.

Market Cap 8.94Cr 7.71Cr 7.26Cr 6.62Cr 12Cr 844.34Cr 12Cr 86Cr 33Cr 431.68Cr 34Cr 33Cr 1.42TCr P/E 2026 *
1.05x
P/E 2027 * -2.68x
Enterprise Value 8.94Cr 7.71Cr 7.26Cr 6.62Cr 12Cr 844.34Cr 12Cr 86Cr 33Cr 431.68Cr 34Cr 33Cr 1.42TCr EV / Sales 2026 *
1.13x
EV / Sales 2027 * 0.79x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.31%
1 week-3.74%
Current month-1.10%
1 month-1.99%
3 months+2.08%
6 months-18.03%
Current year-26.09%
1 week 2.63
Extreme 2.63
2.88
1 month 2.57
Extreme 2.57
3.06
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.15
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Financial Officer

2,967 0.0096%
18/03/26 Free

Chief Executive Officer

4,75,424 1.5318%
18/03/26 Free

Director

4,75,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
+1.31%-3.74%-9.23%-49.30% 8.94Cr
+3.21%+4.39%+47.18%+3.36% 8.23TCr
-3.44%+0.57%+522.22%+37.63% 6.16TCr
+0.89%+0.12%-17.32%-35.39% 5.9TCr
-1.25%-5.30%-1.98%+33.18% 5.12TCr
+0.92%-0.23%+11.50%+169.82% 4.83TCr
+3.93%+1.10%+60.06%-16.07% 3.19TCr
+2.83%+0.44%+49.67%+103.37% 2.53TCr
+0.20%+1.70%-3.42%+190.03% 2.26TCr
-0.52%-1.98%+65.45%+110.84% 1.66TCr
Average +0.82%-2.78%+72.41%+54.75% 3.99TCr
Weighted average by Cap. +0.71%-2.77%+99.42%+46.71%

Financials

2026 *2027 *
Net sales 7.88Cr 6.8Cr 6.4Cr 5.83Cr 11Cr 744.33Cr 11Cr 76Cr 29Cr 380.55Cr 30Cr 29Cr 1.25TCr 11Cr 9.77Cr 9.2Cr 8.39Cr 16Cr 1.07TCr 16Cr 108.96Cr 42Cr 546.96Cr 43Cr 42Cr 1.8TCr
Net income 8.82Cr 7.61Cr 7.17Cr 6.53Cr 12Cr 833.63Cr 12Cr 85Cr 33Cr 426.21Cr 33Cr 32Cr 1.4TCr -3.78Cr -3.26Cr -3.07Cr -2.8Cr -5.23Cr -357.21Cr -5.27Cr -36Cr -14Cr -182.63Cr -14Cr -14Cr -599.93Cr
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
03/26/03 $2.705 +0.93% 2,02,929
01/26/01 $2.680 -2.01% 6,05,780
31/26/31 $2.735 -1.26% 3,26,337
28/26/28 $2.770 -1.07% 3,09,687
27/26/27 $2.800 -0.36% 4,63,476
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.680USD
Average target price
11.00USD
Spread / Average Target
+310.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock